Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on October 16, 2018. The filing primarily discloses the Company's intention to conduct a private offering of convertible senior notes and provides associated risk disclosures under Regulation FD.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period. The primary financial data disclosed relates to a proposed capital raise:
- Proposed Offering: $125.0 million aggregate principal amount of convertible senior notes due 2025.
- Over-Allotment Option: Initial purchasers may be granted an option to purchase up to an additional $18.75 million in notes.
- Previous Equity Issuances: The filing references 6.8 million shares of Class A common stock issued for the Valence Health acquisition and 3,120,301 shares of Class B common stock (convertible to Class A) issued for the New Century acquisition.
- Contingent Consideration: New Century management may be eligible for up to $20.0 million in earnout consideration based on 2019 operating results.
Material Changes and Recent Acquisitions
The Company has recently expanded its portfolio through several acquisitions, which are cited as sources of both growth and risk:
- Recent Acquisitions: Completed acquisitions of Valence Health (Oct 2016), Aldera (Nov 2016), assets from NMHC (Jan 2018), and New Century (Oct 2018).
- Terminated Deal: The Company terminated an agreement to purchase Premier Health Plan in December 2017.
- Operational Shift: The acquisition of New Century introduces significant exposure to "performance-based contracts" where the Company assumes responsibility for a portion of treatment costs in exchange for fixed fees.
Outlook, Risks, and Management Commentary
Management highlights several material risks that could impact future financial performance and liquidity:
- Convertible Note Risks: The conditional conversion feature of the new notes may require cash settlement, adversely affecting liquidity. Additionally, accounting rules (ASC 470-20) may require the recording of higher non-cash interest expense, potentially lowering reported net income.
- Integration Risks: The Company faces challenges integrating recent acquisitions, including potential unanticipated costs, diversion of management resources, and the risk of failing to realize synergies.
- Internal Controls: The Company previously identified a material weakness in internal controls over financial reporting for fiscal years 2016 and 2017. While management believes this was remediated as of June 30, 2018, the independent auditor has not yet confirmed this assessment for the 2018 fiscal year.
- Market Volatility: The rapidly evolving U.S. healthcare market and regulatory changes create uncertainty in forecasting demand and growth rates.
Investor Verification Checklist
- Verify the final terms and closing status of the $125.0 million convertible senior notes offering.
- Confirm the independent auditor's opinion on the effectiveness of internal controls for the fiscal year ended December 31, 2018.
- Monitor the integration progress and financial performance of the New Century acquisition, specifically regarding performance-based contract margins.
- Review future filings for any material changes to the earnout conditions for New Century management.
- Assess the impact of ASC 470-20 accounting treatment on future reported interest expenses and net income.